Evaluation of feasibilty, safety and pleiotropic effects of dapagliflozin -Multicenter trial
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors InterSciences
- 13 Jul 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 04 May 2017 Planned initiation date changed from 1 Feb 2017 to 1 May 2017.
- 04 Feb 2017 New trial record